- Home
- NEN vs LRMR Comparison
NEN vs LRMR Comparison
Compare NEN & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NEN
- LRMR
- Stock Information
- Founded
- NEN 1977
- LRMR N/A
- Country
- NEN United States
- LRMR United States
- Employees
- NEN N/A
- LRMR N/A
- Industry
- NEN Building operators
- LRMR Biotechnology: Pharmaceutical Preparations
- Sector
- NEN Real Estate
- LRMR Health Care
- Exchange
- NEN Nasdaq
- LRMR Nasdaq
- Market Cap
- NEN 262.4M
- LRMR 309.8M
- IPO Year
- NEN N/A
- LRMR N/A
- Fundamental
- Price
- NEN $71.02
- LRMR $3.93
- Analyst Decision
- NEN
- LRMR Strong Buy
- Analyst Count
- NEN 0
- LRMR 8
- Target Price
- NEN N/A
- LRMR $17.88
- AVG Volume (30 Days)
- NEN 329.0
- LRMR 1.3M
- Earning Date
- NEN 01-01-0001
- LRMR 10-29-2025
- Dividend Yield
- NEN 6.75%
- LRMR N/A
- EPS Growth
- NEN 34.86
- LRMR N/A
- EPS
- NEN 4.59
- LRMR N/A
- Revenue
- NEN $83,884,808.00
- LRMR N/A
- Revenue This Year
- NEN N/A
- LRMR N/A
- Revenue Next Year
- NEN N/A
- LRMR N/A
- P/E Ratio
- NEN $15.48
- LRMR N/A
- Revenue Growth
- NEN 4.96
- LRMR N/A
- 52 Week Low
- NEN $71.00
- LRMR $1.61
- 52 Week High
- NEN $84.00
- LRMR $9.50
- Technical
- Relative Strength Index (RSI)
- NEN 31.17
- LRMR 53.33
- Support Level
- NEN $71.02
- LRMR $3.78
- Resistance Level
- NEN $72.00
- LRMR $4.26
- Average True Range (ATR)
- NEN 0.19
- LRMR 0.27
- MACD
- NEN 0.00
- LRMR 0.00
- Stochastic Oscillator
- NEN 2.01
- LRMR 50.67
About NEN New England Realty Associates Limited Partnership Depositary Receipts Evidencing Units of Limited Partnership
New England Realty Associates LP is engaged in the business of acquiring, developing, holding for investment, operating and selling real estate. The Partnership owns and operates various residential apartments, condominium units and commercial properties located in Massachusetts and New Hampshire. The company generates revenue from rental income from residential and commercial properties recognized over the term of the related lease. The long-term goals of the Partnership are to manage, rent and improve its properties and to acquire additional properties with income and capital appreciation potential as suitable opportunities arise.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.